Regulatory approaches to stimulate innovative renal replacement therapies

Regulations for market access and reimbursement of medical devices vary across jurisdictions, complicating the development of innovative technologies for world-wide use; however, several converging regulatory principles are now emerging. Here we discuss approaches by which regulatory and related agencies can promote innovation and boost the effectiveness of regulatory processes to expedite patient access to innovative technologies, including renal replacement therapies.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Luyckx, V. A., Tonelli, M. & Stanifer, J. W. Bull. World Health Organ. 96, 414–422 (2018).

    Article  Google Scholar 

  2. 2.

    Nexight Group. Kidney Health Initiative https://www.asn-online.org/membership/BlastEmails/files/KHI_RRT_Roadmap1.0_FINAL_102318_web.pdf (2018).

  3. 3.

    Global Medical Technology Alliance. GMTA http://www.globalmedicaltechnologyalliance.org/papers/GMTA%20Global%20Harmonization%20of%20Medical%20Technology%20Regulations.pdf (2018).

  4. 4.

    World Health Organization. WHO Global Model Regulatory Framework for medical devices including in vitro diagnostic medical devices (WHO, 2017).

  5. 5.

    IMDRF MDSAP Working Group. IMDRF http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-151002-mdra-audit-report.pdf (2015).

  6. 6.

    Kristensen, F. B. et al. Value Health 22, 13–20 (2019).

    Article  Google Scholar 

  7. 7.

    Wieringa, F. P. & Sheldon, M. Artificial Organs 44, 111–122 (2020).

    Article  Google Scholar 

  8. 8.

    Benz, H. L. et al. Patient 12, 553–557 (2019).

    Article  Google Scholar 

  9. 9.

    Mavris, M., Furia Helms, A. & Bere, N. Nat. Rev. Drug Discov. 18, 885–886 (2019).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

The authors thank the Regulatory Affairs Professionals Society (RAPS) members A. Saaman (DebioTech), A. Purde (TÜV-SÜD) and K. Trautman (NSF International), as well as International Professional Society for Health Economics and Outcomes Research (ISPOR) members B. Gingles (Cook Medical) and T. Tesoro (ISPOR) for reviewing and providing input into this article. The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agency/agencies or organizations with which the author(s) is/are employed/affiliated.

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Fokko P. Wieringa or Murray I. Sheldon or Ana Hidalgo-Simon.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Related links

International Medical Device Regulators Forum (IMDRF): http://www.imdrf.org/

International Professional Society for Health Economics and Outcomes Research (ISPOR): https://www.ispor.org/

Kidney Health Initiative: https://khi.asn-online.org/

Regulatory Affairs Professionals Society (RAPS): https://www.raps.org/

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wieringa, F.P., Sheldon, M.I. & Hidalgo-Simon, A. Regulatory approaches to stimulate innovative renal replacement therapies. Nat Rev Nephrol 16, 546–547 (2020). https://doi.org/10.1038/s41581-020-0275-8

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing